8-89982791-C-T

Variant summary

Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_002485.5(NBN):​c.102G>A​(p.Leu34Leu) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.336 in 1,612,414 control chromosomes in the GnomAD database, including 92,617 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.33 ( 8479 hom., cov: 32)
Exomes 𝑓: 0.34 ( 84138 hom. )

Consequence

NBN
NM_002485.5 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:17

Conservation

PhyloP100: -0.137
Variant links:
Genes affected
NBN (HGNC:7652): (nibrin) Mutations in this gene are associated with Nijmegen breakage syndrome, an autosomal recessive chromosomal instability syndrome characterized by microcephaly, growth retardation, immunodeficiency, and cancer predisposition. The encoded protein is a member of the MRE11/RAD50 double-strand break repair complex which consists of 5 proteins. This gene product is thought to be involved in DNA double-strand break repair and DNA damage-induced checkpoint activation. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.52).
BP6
Variant 8-89982791-C-T is Benign according to our data. Variant chr8-89982791-C-T is described in ClinVar as [Benign]. Clinvar id is 183697.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr8-89982791-C-T is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-0.137 with no splicing effect.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.436 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
NBNNM_002485.5 linkc.102G>A p.Leu34Leu synonymous_variant Exon 2 of 16 ENST00000265433.8 NP_002476.2 O60934

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
NBNENST00000265433.8 linkc.102G>A p.Leu34Leu synonymous_variant Exon 2 of 16 1 NM_002485.5 ENSP00000265433.4 O60934

Frequencies

GnomAD3 genomes
AF:
0.333
AC:
50535
AN:
151880
Hom.:
8469
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.314
Gnomad AMI
AF:
0.266
Gnomad AMR
AF:
0.352
Gnomad ASJ
AF:
0.315
Gnomad EAS
AF:
0.453
Gnomad SAS
AF:
0.436
Gnomad FIN
AF:
0.354
Gnomad MID
AF:
0.282
Gnomad NFE
AF:
0.322
Gnomad OTH
AF:
0.343
GnomAD3 exomes
AF:
0.354
AC:
88873
AN:
251400
Hom.:
15941
AF XY:
0.355
AC XY:
48294
AN XY:
135866
show subpopulations
Gnomad AFR exome
AF:
0.318
Gnomad AMR exome
AF:
0.354
Gnomad ASJ exome
AF:
0.321
Gnomad EAS exome
AF:
0.456
Gnomad SAS exome
AF:
0.428
Gnomad FIN exome
AF:
0.355
Gnomad NFE exome
AF:
0.325
Gnomad OTH exome
AF:
0.335
GnomAD4 exome
AF:
0.336
AC:
490907
AN:
1460416
Hom.:
84138
Cov.:
35
AF XY:
0.338
AC XY:
245823
AN XY:
726624
show subpopulations
Gnomad4 AFR exome
AF:
0.318
Gnomad4 AMR exome
AF:
0.358
Gnomad4 ASJ exome
AF:
0.318
Gnomad4 EAS exome
AF:
0.480
Gnomad4 SAS exome
AF:
0.429
Gnomad4 FIN exome
AF:
0.362
Gnomad4 NFE exome
AF:
0.322
Gnomad4 OTH exome
AF:
0.344
GnomAD4 genome
AF:
0.333
AC:
50581
AN:
151998
Hom.:
8479
Cov.:
32
AF XY:
0.338
AC XY:
25081
AN XY:
74274
show subpopulations
Gnomad4 AFR
AF:
0.314
Gnomad4 AMR
AF:
0.352
Gnomad4 ASJ
AF:
0.315
Gnomad4 EAS
AF:
0.451
Gnomad4 SAS
AF:
0.437
Gnomad4 FIN
AF:
0.354
Gnomad4 NFE
AF:
0.322
Gnomad4 OTH
AF:
0.347
Alfa
AF:
0.313
Hom.:
9887
Bravo
AF:
0.329
Asia WGS
AF:
0.425
AC:
1479
AN:
3478
EpiCase
AF:
0.319
EpiControl
AF:
0.317

ClinVar

Significance: Benign
Submissions summary: Benign:17
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:6
Mar 28, 2016
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Disclaimer: This variant has not undergone full assessment. The following are pr eliminary notes: Frequency -

-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Jan 24, 2024
Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is classified as Benign based on local population frequency. This variant was detected in 63% of patients studied by a panel of primary immunodeficiencies. Number of patients: 60. Only high quality variants are reported. -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

-
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Microcephaly, normal intelligence and immunodeficiency Benign:5
Sep 16, 2020
Natera, Inc.
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Feb 01, 2025
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Jul 01, 2021
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

not provided Benign:3
-
Breakthrough Genomics, Breakthrough Genomics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: not provided

- -

Nov 01, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Mar 03, 2015
GeneDx
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Acute lymphoid leukemia Benign:1
Jul 07, 2023
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Hereditary cancer-predisposing syndrome Benign:1
Nov 18, 2014
Ambry Genetics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Hereditary breast ovarian cancer syndrome Benign:1
Apr 19, 2022
National Health Laboratory Service, Universitas Academic Hospital and University of the Free State
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.52
CADD
Benign
3.1
DANN
Benign
0.88
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs1063045; hg19: chr8-90995019; COSMIC: COSV55371979; COSMIC: COSV55371979; API